긴 관상동맥 병변에 대한 제1세대 및 2세대 약물용출 스텐트 중첩 시술 후 2년간 임상 경과의 비교 = Comparison of Clinical Outcomes after Implantation of First- and Second-Generation Overlapping Drug-Eluting Stents to Treat Diffuse Long Coronary Lesions

다국어 초록 (Multilingual Abstract)

Background/Aims: Despite improved revascularization techniques, the clinical outcomes of patients with diffuse coronary artery lesions after percutaneous coronary intervention are unsatisfactory. However, few studies have compared the efficacy of first- and second-generation drug-eluting stents (DES) in patients with diffuse long coronary artery lesions. Methods: Between January 2006 and July 2012, 364 patients who were treated with DES for long coronary artery stenosis (> 30 mm) were enrolled in this study and assigned to either Group I (first-generation DES, 62.3 ± 10.4 years, 136 males, n = 183) or Group II (second-generation DES, 64.3 ± 10.7 years, 134 males, n = 181). The incidence of major adverse cardiac events (MACE) was compared between the two groups over 2 years of follow-up, and predictive factors associated with MACE were evaluated through a multivariate analysis. Results: Although several coronary angiographic characteristics were different between the two groups, most demographic and baseline clinical variables were the same. The cumulative incidence of MACE was significantly higher in Group I than in Group II (25.7 vs. 6.6%, p < 0.001), mainly due to reduced target lesion revascularization (21.9 vs. 2.2%, p < 0.001). According to the results of the multivariate analysis, the use of a paclitaxel-eluting stent (PES) (hazard ratio [HR], 5.168, 95% confidence interval [CI], 2.515-10.617, p < 0.001), decreased left ventricular function (≤ 45%, HR, 3.586, 95% CI, 1.839-6.990, p < 0.001), and diabetes mellitus (HR, 2.984, 95% CI, 1.605-5.548, p < 0.001) were independent contributors to MACE.

참고문헌 (Reference)

1 이선화, "약물용출 스텐트를 이용한 Full Metal Jacket (≥60 mm) 시술의 단기 및 장기 성적" 대한심장학회 38 (38): 87-94, 2008

2 김원, "미만성 관상동맥병변에 대한 약물 용출성스텐트 중첩 시술의 재협착 예방 효과" 대한심장학회 36 (36): 17-23, 2006

3 양태현, "급성 ST절 상승 심근경색환자에서 일차적 스텐트 삽입술 시행 시 시로리무스 용출성 스텐트의 효과와 안전성" 대한심장학회 35 (35): 672-676, 2005

4 Ciçek D, "Two-year outcome of Turkish patients treated with Zotarolimus versus Paclitaxel eluting stents in an unselected population with coronary artery disease in the real world: a prospective non-randomized registry in southern Turkey" 8 : 68-73, 2011

5 Li XT, "Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimuseluting stents" 25 : 405-411, 2014

6 Nojima Y, "Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis" 25 : 638-644, 2014

7 Kedhi E, "Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial" 375 : 201-209, 2010

8 Yan P, "Second- versus first-generation drugeluting stents for diabetic patients: a meta-analysis" 10 : 213-221, 2014

9 Kitabata H, "Safety and efficacy outcomes of overlapping second-generation everolimuseluting stents versus first-generation drug-eluting stents" 112 : 1093-1098, 2013

10 Waksman R, "Safety and efficacy of the XIENCE V everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice" 109 : 1288-1294, 2012

11 Khurshid Ahmed, "Safety and Efficacy of Overlapping Homogenous Drug-Eluting Stents in Patients with Acute Myocardial Infarction: Results from Korea Acute Myocardial Infarction Registry" 대한의학회 27 (27): 1339-1346, 2012

12 Shammas NW, "Outcomes of patients treated with the everolimus-eluting stent versus the zotarolimus eluting stent in a consecutive cohort of patients at a tertiary medical center" 8 : 205-211, 2012

13 Tsagalou E, "Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery" 45 : 1570-1573, 2005

14 Her SH, "Long-term clinical outcomes of overlapping heterogeneous drug-eluting stents compared with homogeneous drug-eluting stents" 97 : 1501-1506, 2011

15 Lim SY, "Inflammation and delayed endothelization with overlapping drug-eluting stents in a porcine model of in-stent restenosis" 72 : 463-468, 2008

16 Räber L, "Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation" 55 : 1178-1188, 2010

17 Man SC, "Gated SPECT:what's the ideal method to measure LVEF?" 24 : 807-810, 2008

18 Manginas A, "Estimation of coronary flow reserve using the Thrombolysis In Myocardial Infarction (TIMI) frame count method" 83 : 1562-1565,A7, 1999

19 Erbel R, "Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group" 339 : 1672-1678, 1998

20 Kandzari DE, "Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial" 48 : 2440-2447, 2006

21 Maeng M, "Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: a study from the Western Denmark Heart Registry" 12 : 84-, 2012

22 Lee MG, "Comparison of paclitaxel-, sirolimus-, and zotarolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction and metabolic syndrome" 75 : 2120-2127, 2011

23 Kitabata H, "Comparison of long-term outcomes between everolimus-eluting and sirolimus-eluting stents in small vessels" 111 : 973-978, 2013

24 Cho SC, "Clinical outcomes of everolimus-and zotarolimus-eluting stents in patients with acute myocardial infarction for small coronary artery disease" 63 : 409-417, 2014

25 Dvir D, "Clinical outcomes after treating acute coronary syndrome patients with a drugeluting stent: results from REWARDS-EMI (Endeavor for Myocardial Infarction Registry)" 14 : 128-133, 2013

26 Lee CW, "Clinical and angiographic outcomes after placement of multiple overlapping drugeluting stents in diffuse coronary lesions" 98 : 918-922, 2006

27 박종선, "Clinical and Angiographic Outcome of Sirolimus-ElutingStent for the Treatment of Very Long Lesions" 대한심장학회 36 (36): 490-494, 2006

28 Biondi-Zoccai G, "Appraising the impact of left ventricular ejection fraction on outcomes of percutaneous drug-eluting stenting for unprotected left main disease: insights from a multicenter registry of 975 patients" 100 : 403-411, 2011

29 Mehran R, "Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome" 100 : 1872-1878, 1999

30 Chevalier B, "A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial" 1 : 524-532, 2008

31 Fischman DL, "A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators" 331 : 496-501, 1994

32 Schömig A, "A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease" 50 : 1373-1380, 2007

33 Serruys PW, "A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group" 331 : 489-495, 1994